In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's implantable drug pump approved in US:

This article was originally published in Clinica

Executive Summary

Medtronic has received US FDA approval for its IsoMed constant-flow infusion system, an implantable drug pump for the treatment of colorectal liver cancer. The pump is surgically placed under the skin of the abdomen and delivers cancer-fighting medication directly to the liver, assisted by a catheter that runs from the pump to the hepatic artery. The system can also deliver morphine sulphate directly into spinal fluid as a treatment for chronic back pain, said the Minneapolis, Minnesota-based company.

You may also be interested in...



Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov

Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 

Novartis Payments For Kymriah Treatment Logistics Avoid Kickback Concerns

US HHS Office of Inspector General clears company program to provide travel expenses and lodging to needy patients located far from designated treatment centers.

Topics

UsernamePublicRestriction

Register

MT076829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel